
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Feb 08, 2026 00:59 am UTC| Business Health Governance
Hims Hers Health announced on Saturday that it will stop offering access to its compounded semaglutide pill following a warning from the U.S. Food and Drug Administration, which said it would take action against the...

Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Feb 08, 2026 00:42 am UTC| Health Business
Pharmaceutical and telehealth companies are spending millions of dollars on celebrity-driven Super Bowl ads as competition heats up in the fast-growing weight-loss drug market. Brands behind GLP-1 weight-loss medications,...

FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Feb 07, 2026 03:05 am UTC| Governance Health Business
The U.S. Food and Drug Administration (FDA) announced on Friday that it will take enforcement action against telehealth provider Hims Hers over its $49 weight-loss pill, escalating scrutiny of compounded GLP-1 drugs sold...

TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Feb 07, 2026 02:44 am UTC| Health Politics
President Donald Trump has launched a new prescription drug pricing website, TrumpRx.gov, aiming to showcase his administrations efforts to reduce drug costs in the United States. The website focuses heavily on negotiated...

Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition
Feb 04, 2026 02:05 am UTC| Business Health
Novo Nordisk, the maker of blockbuster weight-loss drug Wegovy, has warned that profits and sales could fall by as much as 13% this year, marking its first potential decline in years. The Danish pharmaceutical giant cited...

RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
Jan 29, 2026 01:35 am UTC| Health Governance
U.S. Health Secretary Robert F. Kennedy Jr. has reshaped national autism policy by appointing an entirely new slate of 21 members to the Interagency Autism Coordinating Committee (IACC), a federal panel that provides...

Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Jan 23, 2026 07:26 am UTC| Business Health
Sanofi (EPA: SASY) has announced encouraging late-stage clinical trial results for its investigational drug amlitelimab, reinforcing its potential as a new treatment option for patients with moderate to severe eczema. The...